CER-2021-0131 Supplementary Materials: Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC

Supplementary MaterialsoCensoringoStatistical methodsoSensitivity analysesoUnadjusted resultsoPropensity scoreSupplementary Tables 1-7oSupplementary Table 1. Censoring rules for TTD, PFS, and OS.oSupplementary Table 2. Propensity score matching.oSupplementary Table 3. Comparison of results of the Cox pro-portional hazard model using BICR or investigator-assessed progression in the trial.oSupplementary Table 4. Landmark analyses at 1 and 3 months for TTD and PFS.oSupplementary Table 5. Sensitivity analysis of the TTD.oSupplementary Table 6. Subgroup analysis by CNS status: unad-justed TTD and PFS.oSupplementary Table 7. Multivariate Cox model of treatment effect by CNS status.Supplementary Figure 1. Swimmer plot of patients receiving treatment beyond progression (TBP) in the crizotinib cohort (37 out of 65 patients received TBP).